BIO.News Newsletter

With drug price controls under consideration in the Senate, new analysis shows how they would devastate drug development and new treatments. On World Hepatitis Day, we look at why this preventable, treatable virus is still a threat. (740 words, 3 minutes, 42 seconds) P.S. The BIO Impact Agriculture & Environment conference is right around the corner. Be sure to register today.

Ending the week with what USTR nominee Doug McKalip said about agricultural biotech trade with Mexico and Korea, plus a new report that shows the dire need to invest in public health infrastructure and preparedness. (783 words, 3 minutes, 54 seconds)

A new report finds the patchwork of state regulations regarding Medicaid coverage for new, innovative treatments can create barriers for patients seeking access to the most advanced therapies. Meanwhile, it’s getting hotter on Earth—and biotech is helping us explore new possibilities for growing food in space. (774 words, 3 minutes, 52 seconds)

With everyone talking about drug pricing, we have an exclusive look at why we need to think about value rather than cost. Plus, we’re celebrating Dr. Rosalind Franklin’s birthday—and looking for the next biotech game-changers. (699 words, 3 minutes, 29 seconds)

Over the weekend, WHO declared monkeypox a health emergency of international concern—we tell you what that means and what’s happening in the U.S. Plus, recent CBO analysis of proposed drug price controls misinforms—and misses the mark, say BIO’s health policy experts. (682 words, 3 minutes, 24 seconds)

Before the weekend, we have a quick read on why we need to fund BARDA and what the FDA Commissioner said about animal feed. (538 words, 2 minutes, 41 seconds)

It was a busy Wednesday. The House passed the Ag-FDA spending bill, which boosts biotech and innovation. Two U.S. Senators (and Dr. Michelle) discussed how and why we need to tackle antimicrobial resistance. Plus, BIO responded to the Berlin Declaration on vaccine access. (764 words, 3 minutes, 49 seconds)

With the Senate considering drug price controls, Congress’s MedPAC finds prices fell for many drugs that would be subject to price setting. Plus, BIO IMPACT returns to an in-person event in September—here’s why it’s so timely. (750 words, 3 minutes, 45 seconds)

The latest data shows drug prices are still rising slower than inflation—so, why are drug manufacturers the target when it comes to controlling health care costs? Plus, a BIO member company launched the first human trial of “base editing,” which could be a game-changer for patients and the potential of gene editing. (667 words, 3 minutes, 20 seconds)

Childhood vaccinations dropped in every region in 2021, says new WHO/UNICEF data—here’s what happened and what we can do about it. Plus, BIO’s Dr. Michelle McMurry-Heath explains how biotech can address America’s nutritional gaps. (638 words, 3 minutes, 11 secondsP.S. It’s not too late to register for BIO Asia-Taiwan, happening July 27-31 both in Taipei and online—but hurry, because pre-registration closes on Wednesday, July 20! Get more details and register now.